Treatment of retinal vasculitis in Behçet's disease with rituximab

Porter SR, Al-Otaibi LM, Poate TWJ. Behçet’s disease: a review. J Dent Res. 2005;84:209–22.

Kansu T, Kadayifcilar S. Visual aspects of Behçet’s disease. Curr Treat Options Neurol. 2007;8:81–8.

Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125:1678–85.

Davachi F. New and innovative therapies for Behçet’s disease. APLAR J Rheum. 2004;7:141–5.

Kneitz C, Wilhelm M, Tony H. Effective B cell depletion with rituximab in treatment of autoimmune diseases. J Immunobiol. 2002;206:519–27.

Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–68.

Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, et al. Efficacy of B-cell–targeted therapy with rituximab in patients with rheumatoid arthritis. New Engl J Med. 2004; 350:2572–81.

Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener’s granulomatosis associated scleritis with rituximab. Br J Ophthalmol. 2005;89:1542.

Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis. 2005;64:1087–8.

Kaushik VV, Reddy HV, BucknalR C. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis. 2006;65:1116–7.

Eksioglu-Demiralp E, Kibaroglu A, Direskeneli H, et al. Phenotypic characteristics of B cells in Behçet's disease: increased activity in B cell subsets. J Rheumatol. 1999;26:826–32.

Looney RJ, Anolik JH, Campbell D, Felgar RE, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580–9.